Evidence map›Paper›PMID 40635629›Full record

ReviewExpert review of proteomics2025

The evolution of analytical techniques for multiplex analysis of protein biomarkers.

Hyeyoon Kim, David Ross Hall, Lorenz Nierves, Tai-Tu Lin, Reta Birhanu Kitata, Tujin Shi, Tao Liu

Abstract readReview
In one paragraph

Review in Expert review of proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hyeyoon KimBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0002-8197-6114
David Ross HallBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0001-9580-1342
Lorenz NiervesBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0001-5545-4323
Tai-Tu LinBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0002-8985-0364
Reta Birhanu KitataBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0002-8973-7679
Tujin ShiBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0002-5592-3588
Tao LiuBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.ORCID 0000-0001-9529-6550

Funding

Center for Advanced Multi-Omic Characterization of CancerU24CA271012 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI Tao Liu · 2022 to 2026
$6.6M
Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein MarkersR01CA258240 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David M. Lubman, Tujin Shi · 2022 to 2026
$2.3M
Targeted proteomics technology for accurate quantitative single-cell proteomicsR01GM139858 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI SHI, TUJIN · 2021 to 2024
$1.6M
NCI NIH HHS R01 CA258240NCI NIH HHS U24 CA271012NIGMS NIH HHS R01 GM139858
6 · The paper itself

Abstract

introductionThe landscape of biomarker development has evolved with advanced analytical technologies, particularly affinity- and mass spectrometry-based techniques. These advancements have deepened our understanding of disease mechanisms, enabling the development of precise diagnostic tools and personalized medicine. Protein biomarkers, which play pivotal roles in biological processes, have become invaluable in diagnosing and monitoring diseases, aided by their presence in various biological samples and the availability of established detection methods. AREAS COVERED: This review covers the role of protein biomarkers in clinical practice, the development and dimensionality of protein biomarkers, advancements in detection technologies, a comparison of these technologies, and future directions in biomarker discovery and disease mechanism elucidation. EXPERT OPINION: Advances in biomarker technologies have the potential to transform diagnostics and personalized treatment but face challenges such as high costs and technical complexity. Enhancing reproducibility and integrating multi-omics approaches may offer better insights. The field should evolve toward high-throughput, automated methods, continuously adapting research, and clinical practices.

Indexed as

BiomarkersProteinsProteomicsHumansMass SpectrometryPrecision MedicineBiomarkersProteinsbiomarker developmentmass spectrometrymultiplex analysisprotein biomarkersProteomics

Identifiers

PMID40635629
PMCPMC12285665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.